Insightful Analysis of Prem Watsa (Trades, Portfolio)'s Fourth Quarter 2024 13F Filing Prem Watsa (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2024, providing insights into his investment moves during this period. Born on August 5, 1950, Prem Watsa (Trades, Portfolio) hails from a small Christian community in Mangalore, India. He pursued chemical engineering at the Indian Institute of Technology before moving to Canada in 1972 with just $8. Watsa completed his MBA at the University of Western Ontario and began his career at Confederation Life. Inspired by Warren Buffett (Trades, Portfolio)'s investment strategies, Watsa founded Fairfax Financial, a holding company focused on property and casualty insurance, reinsurance, and investment management. Fairfax aims to achieve high returns on invested capital through disciplined underwriting and a total return investment approach. Watsa's conservative value investment philosophy emphasizes long-term gains, both realized and unrealized.Prem Watsa's Strategic Moves: CVS Health Corp Takes Center Stage with 7.82% Portfolio Share Summary of New Buy Prem Watsa (Trades, Portfolio) added a total of four stocks, among them: The most significant addition was CVS Health Corp (NYSE:CVS), with 2,712,000 shares, accounting for 7.82% of the portfolio and a total value of $121,741,680 million. The second largest addition to the portfolio was Molson Coors Beverage Co (NYSE:TAP), consisting of 1,186,500 shares, representing approximately 4.37% of the portfolio, with a total value of $68,010,180. The third largest addition was Cleveland-Cliffs Inc (NYSE:CLF), with 5,899,273 shares, accounting for 3.56% of the portfolio and a total value of $55,453,170. Key Position Increases Prem Watsa (Trades, Portfolio) also increased stakes in a total of six stocks, among them: The most notable increase was The Kraft Heinz Co (NASDAQ:KHC), with an additional 2,564,000 shares, bringing the total to 3,314,000 shares. This adjustment represents a significant 341.87% increase in share count, a 5.06% impact on the current portfolio, with a total value of $101,772,940. The second largest increase was ATS Corp (NYSE:ATS), with an additional 2,429,700 shares, bringing the total to 2,486,400. This adjustment represents a significant 4,285.19% increase in share count, with a total value of $73,870,690. Summary of Sold Out Prem Watsa (Trades, Portfolio) completely exited four holdings in the fourth quarter of 2024, as detailed below: Alphabet Inc (NASDAQ:GOOGL): Prem Watsa (Trades, Portfolio) sold all 274,620 shares, resulting in a -4.14% impact on the portfolio. Intel Corp (NASDAQ:INTC): Prem Watsa (Trades, Portfolio) liquidated all 190,000 shares, causing a -0.41% impact on the portfolio. Story Continues Key Position Reduces Prem Watsa (Trades, Portfolio) also reduced positions in two stocks. The most significant changes include: Reduced Capri Holdings Ltd (NYSE:CPRI) by 124,000 shares, resulting in a -61.36% decrease in shares and a -0.48% impact on the portfolio. The stock traded at an average price of $26.96 during the quarter and has returned 15.17% over the past three months and 7.45% year-to-date. Reduced Xeris Biopharma Holdings Inc (NASDAQ:XERS) by 31,250 shares, resulting in a -18.28% reduction in shares and a -0.01% impact on the portfolio. The stock traded at an average price of $3.22 during the quarter and has returned 14.29% over the past three months and 6.19% year-to-date. Portfolio Overview At the fourth quarter of 2024, Prem Watsa (Trades, Portfolio)'s portfolio included 31 stocks. The top holdings included 19.97% in Orla Mining Ltd (ORLA), 19.11% in Occidental Petroleum Corp (NYSE:OXY), 11.35% in BlackBerry Ltd (NYSE:BB), 8.56% in Kennedy-Wilson Holdings Inc (NYSE:KW), and 7.82% in CVS Health Corp (NYSE:CVS).Prem Watsa's Strategic Moves: CVS Health Corp Takes Center Stage with 7.82% Portfolio Share The holdings are mainly concentrated in 10 of the 11 industries: Basic Materials, Energy, Technology, Consumer Defensive, Healthcare, Real Estate, Consumer Cyclical, Industrials, Financial Services, and Communication Services.Prem Watsa's Strategic Moves: CVS Health Corp Takes Center Stage with 7.82% Portfolio Share This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. View Comments
Prem Watsa's Strategic Moves: CVS Health Corp Takes Center Stage with 7.82% Portfolio Share
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...